Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms along with high-dosage statin therapy in hyperlipidemic patients–the PRIMO study. Cardiovasc Drugs Ther 2005;19:403–14.
Cohen JD, Brinton EA, Ito MK, et al. Knowing Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol 2012;6:208–15.
Chowdhury R, Khan H, Heydon E, et al. Adherence to cardio therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J 2013;34:2940–8.
Pasternak RC, Smith SC Jr., Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002;40:567–72.
Mancini GB, Tashakkor AY, Baker S, et al. Diagnosis, prevention, and management of statin side effects and intolerance: Canadian Functioning Group Consensus update. Can easily J Cardiol 2013;29:1553–68.
Rosenson RS, Baker SK, Jacobson TA, et al. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol 2014;8:S58–71.
Alfirevic A, Neely D, Armitage J, et al. Phenotype standardization for statin-induced myotoxicity. Clin Pharmacol Ther 2014;96:470–6.
Norman DJ, Illingworth DR, Munson J, et al. Myolysis and acute renal failure in a hearttransplant recipient receiving lovastatin. N Engl J Med 1988;318:46–7.
Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 2015;36:1012–22.
Panza GA, Taylor BA, Dada MR, et al. Modifications in muscle strength in people along with statin-induced myopathy: a summary of 3 investigations. J Clin Lipidol 2015;9:351–6.
Knochel JP. Catastrophic medical events along with exhaustive exercise: “white collar rhabdomyolysis”. Kidney Int 1990;38:709–19.
Parker BA, Capizzi JA, Grimaldi AS, et al. Effect of statins on skeletal muscle function. Circulation 2013;127:96–103.
Taylor BA, Lorson L, White CM, et al. A randomized trial of coenzyme Q10 in patients along with confirmed statin myopathy. Atherosclerosis 2015;238:329–35.
Buettner C, Rippberger MJ, Smith JK, et al. Statin use and musculoskeletal pain among adults along with and devoid of arthritis. Am J Med 2012;125:176–82.
Ganga HV, Slim HB, Thompson PD. A systematic review of statin-induced muscle issues in clinical trials. Am Heart J 2014;168:6–15.
Siegel AJ, Silverman LM, Lopez RE. Creatine kinase elevations in marathon runners: partnership to training and competition. Yale J Biol Med 1980;53:275–9.
Clarkson PM, Kearns AK, Rouzier P, et al. Serum creatine kinase levels and renal function measures in exertional muscle damage. Med Sci Sports Exerc 2006;38:623–7.
Thompson PD, Zmuda JM, Domalik LJ, et al. Lovastatin boosts exercise-induced skeletal muscle injury. Metabolism 1997;46:1206–10.
Parker BA, Augeri AL, Capizzi JA, et al. Effect of statins on creatine kinase levels prior to and after a marathon run. Am J Cardiol 2012;109:282–7.
Hedenmalm K, Alvan G, Ohagen P, et al. Muscle toxicity along with statins. Pharmacoepidemiol Drug Saf 2010;19:223–31.
Andrade SE, Graham DJ, Staffa JA, et al. Healthiness strategy administrative databases Can easily efficiently identify severe myopathy and rhabdomyolysis. J Clin Epidemiol 2005;58:171–4.
Cziraky MJ, Willey VJ, McKenney JM, et al. Risk of hospitalized rhabdomyolysis associated along with lipid-lowering drugs in a real-globe clinical setting. J Clin Lipidol 2013;7:102–8.
Schech S, Graham D, Staffa J, et al. Risk factors for statin-associated rhabdomyolysis. Pharmacoepidemiol Drug Saf 2007;16:352–8.
Banach M, Rizzo M, Toth PP, et al. Statin intolerance – an attempt at a unified definition. Placement paper from an Global Lipid Expert Panel. Expert Opin Drug Saf 2015;14:935–55.
Bellosta S, Corsini A. Statin drug interactions and related side reactions. Expert Opin Drug Saf 2012;11:933–46.
Guengerich FP. Cytochrome P450 and chemical toxicology. Chem Res Toxicol 2008;21:70–83.
Sorokin AV, Duncan B, Panetta R, et al. Rhabdomyolysis associated along with pomegranate juice consumption. Am J Cardiol 2006;98:705–6.
Livalo [package insert]. Montgomery AL: Kowa Pharmaceuticals America, Inc., 2012.
Bailey DG, Malcolm J, Arnold O, et al. Grapefruit juice-drug interactions. Br J Clin Pharmacol 1998;46:101–10.
SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy–a genomewide study. N Engl J Med 2008;359:789–99.
Canestaro WJ, Austin MA, Thummel KE. Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review. Genet Med 2014;16:810–9.
Knauer MJ, Urquhart BL, Meyer zu Schwabedissen HE, et al. Human skeletal muscle drug transporters find out local exposure and toxicity of statins. Circ Res 2010;106:297–306.
Olbricht C, Wanner C, Eisenhauer T, et al. Accumulation of lovastatin, yet not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther 1997;62:311–21.
Bramow S, Ott P, Thomsen Nielsen F, et al. Cholestasis and regulation of genes related to drug metabolism and biliary transport in rat liver adhering to treatment along with cyclosporine A and sirolimus (Rapamycin). Pharmacol Toxicol 2001;89:133–9.
Prueksaritanont T, Zhao JJ, Ma B, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 2002;301:1042–51.
Prueksaritanont T, Subramanian R, Fang X, et al. Glucuronidation of statins in pet dogs and humans: a novel mechanism of statin lactonization. Drug Metab Dispos 2002;30:505–12.
FDA: Limit use of 80 mg Simvastatin. FDA Consumer Healthiness Information, June 2011. U.S. Meals and Drug Administration. 2011. Available at: http://ift.tt/28Jcvgb. Accessed March 12, 2016.
de Lemos JA, Blazing MA, Wiviott SD, et al., A to Z Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients along with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292:1307–16.
Study of the Effectiveness of Additional Reductions in Cholesterol levels and Homocysteine (SEARCH) Collaborative Group. Intensive lowering of LDL Cholesterol levels along with 80 mg versus twenty mg simvastatin everyday in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet 2010;376:1658–69.
Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681–90.
Grable-Esposito P, Katzberg HD, Greenberg SA, et al. Immune-mediated necrotizing myopathy associated along with statins. Muscle Nerve 2010;41:185–90.
Mammen AL, Chung T, Christopher-Stine L, et al. Autoantibodies versus 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients along with statin-associated autoimmune myopathy. Arthritis Rheum 2011;63:713–21.
Mohassel P, Mammen AL. Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies. Muscle Nerve 2013;48:477–83.
Michalska-Kasiczak M, Sahebkar A, Mikhailidis DP, et al., Lipid and Blood Tension Meta-analysis Collaboration (LBPMC) Group. Analysis of vitamin D levels in patients along with and devoid of statin-associated myalgia – a systematic review and meta-analysis of 7 studies along with 24twenty patients. Int J Cardiol 2015;178:111–6.
Khayznikov M, Hemachrandra K, Pandit R, et al. Statin intolerance as a result of myalgia, myositis, myopathy, or myonecrosis Can easily in most cases be safely resolved by vitamin D supplementation. N Am J Med Sci 2015;7:86–93.
Banach M, Serban C, Sahebkar A, et al., Lipid and Blood Tension Meta-analysis Collaboration (LBPMC) Group. P5981: Futility of supplementation along with Coenzyme Q10 for statin-induced myopathy: an updated (2015) meta-analysis of randomized controlled trials. Eur Heart J 2015;36:1047 (abstr).
Nielsen SF, Nordestgaard BG. Negative statin-related news stories decrease statin persistence and improve myocardial infarction and cardio mortality: a nationwide prospective cohort study. Eur Heart J 2016;37:908–16.
Nocebo. Wikipedia, The Free Encyclopedia. 2016. Available at: http://ift.tt/1u9wUdG. Accessed March 12, 2016.
Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in book care settings: a cohort study. Ann Intern Med 2013;158:526–34.
Juszczyk MA, Seip RL, Thompson PD. Decreasing LDL Cholesterol levels and medication cost along with every-other-day statin therapy. Prev Cardiol 2005;8:197–9.
Keating AJ, Campbell KB, Guyton JR. Intermittent nondaily dosing strategies in patients along with previous statin-induced myopathy. Ann Pharmacother 2013;47:398–404.
Gadarla M, Kearns AK, Thompson PD. Efficacy of rosuvastatin (5 mg and 10 mg) two times a week in patients intolerant to everyday statins. Am J Cardiol 2008;101:1747–8.
AIM-higher Investigators. Niacin in patients along with reasonable HDL Cholesterol levels levels receiving intensive statin therapy. N Engl J Med 2011;365:2255–67.
HPS2-THRIVE Collaborative Group. Effects of extended-release niacin along with laropiprant in high-risk patients. N Engl J Med 2014;371:203–12.
Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long term benefit along with niacin. J Am Coll Cardiol 1986;8:1245–55.
Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol 2007;99:410–4.
The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351–64.
Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial along with gemfibrozil in middle-aged men along with dyslipidemia. Safety of treatment, Modifications in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237–45.
ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563–74.
Cao P, Hanai J, Tanksale P, et al. Statin-induced muscle damage and atrogin-1 induction is the result of a geranylgeranylation defect. FASEB J 2009;23:2844–54.
Draeger A, Monastyrskaya K, Mohaupt M, et al. Statin therapy causes ultrastructural damage in skeletal muscle in patients devoid of myalgia. J Pathol 2006;210:94–102.
Päivä H, Thelen KM, Van Coster R, et al. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther 2005;78:60–8.
Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol 2007;49:2231–7.
Hoffman EP, Nader GA. Balancing muscle hypertrophy and atrophy. Nat Med 2004;10:584–5.
Mallinson JE, Constantin-Teodosiu D, Sidaway J, et al. Blunted Akt/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy. J Physiol 2009;587:219–30.
Hanai J, Cao P, Tanksale P, et al. The muscle-individual ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. J Clin Invest 2007;117:3940–51.
Urso ML, Clarkson PM, Hittel D, et al. Modifications in ubiquitin proteasome pathway gene expression in skeletal muscle along with workout and statins. Arterioscler Thromb Vasc Biol 2005;25:2560–6.
Mallinson JE, Marimuthu K, Murton A, et al. Statin myalgia is not associated along with reasonable muscle strength, mass or healthy protein turnover in older male volunteers, yet is allied along with a slowing of time to peak energy output, insulin resistance and differential muscle mRNA expression. J Physiol 2015;593:1239–57.
Thompson PD, Parker B. Statins, exercise, and workout training. J Am Coll Cardiol 2013;62:715–6.
Buettner C, Lecker SH. Molecular basis for statin-induced muscle toxicity: implications and possibilities. Pharmacogenomics 2008;9:1133–42.
Mikus CR, Boyle LJ, Borengasser SJ, et al. Simvastatin impairs workout training adaptations. J Am Coll Cardiol 2013;62:709–14.
Larsen S, Stride N, Hey-Mogensen M, et al. Simvastatin effects on skeletal muscle: relation to decreased mitochondrial function and glucose intolerance. J Am Coll Cardiol 2013;61:44–53.
Itagaki M, Takaguri A, Kano S, et al. Feasible mechanisms underlying statin-induced skeletal muscle toxicity in L6 fibroblasts and in rats. J Pharmacol Sci 2009;109:94–101.
Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001;103:357–62.
Ridker PM, Danielson E, Fonseca FA, et al., JUPITER Study Group. Rosuvastatin to steer clear of vascular events in men and women along with elevated C-reactive protein. N Engl J Med 2008;359:2195–207.
Yudkin JS, Stehouwer CD, Emeis JJ, et al. Creactive healthy protein in healthy and balanced subjects: associations along with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999;19:972–8.
Swerdlow DI, Preiss D, Kuchenbaecker KB, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet 2015;385:351–61.
Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes along with intensive-dose compared along with moderate-dose statin therapy: a metaanalysis. JAMA 2011;305:2556–64.
Ridker PM, Pradhan A, MacFadyen JG, et al. cardio benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012;380:565–71.
Mora S, Glynn RJ, Hsia J, et al. Statins for the primary prevention of cardio events in women along with elevated high-sensitivity C-reactive healthy protein or dyslipidemia: outcomes from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation 2010;121:1069–77.
Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735–42.
Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women’s Healthiness Initiative. Arch Intern Med 2012;172:144–52.
HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-explained muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013;34:1279–91.
Besseling J, Kastelein JJ, Defesche JC, et al. Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus. JAMA 2015;313:1029–36.
Xia F, Xie L, Mihic A, et al. Inhibition of Cholesterol levels biosynthesis impairs insulin secretion and voltage-gated calcium channel function in pancreatic b-cells. Endocrinology 2008;149:5136–45.
Kusminski CM, Scherer PE. Mitochondrial dysfunction in white adipose tissue. Trends Endocrinol Metab 2012;23:435–43.
Supale S, Li N, Brun T, et al. Mitochondrial dysfunction in pancreatic b cells. Trends Endocrinol Metab 2012;23:477–87.
Nakata M, Nagasaka S, Kusaka I, et al. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia 2006;49:1881–92.
Chamberlain LH. Inhibition of isoprenoid biosynthesis sets off insulin resistance in 3T3-L1 adipocytes. FEBS Lett 2001;507:357–61.
Meng XF, Yu JT, Wang HF, et al. Midlife vascular risk factors and the risk of Alzheimer’s disease: a systematic review and meta-analysis. J Alzheimers Dis 2014;42:1295–310.
Wagstaff LR, Mitton MW, Arvik BM, et al. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy 2003;23:871–80.
Evans WJ, Cannon JG. The metabolic effects of exercise-induced muscle damage. Exerc Sport Sci Rev 1991;19:99–125.
Muldoon MF, Barger SD, Ryan CM, et al. Effects of lovastatin on cognitive function and psychological well-being. Am J Med 2000;108:538–46.
Muldoon MF, Ryan CM, Sereika SM, et al. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med 2004;117:823–9.
Yaffe K, Barrett-Connor E, Lin F, et al. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol 2002;59:378–84.
Bernick C, Katz R, Smith NL, et al., cardio Healthiness Study Collaborative Research Group. Statins and cognitive function in the elderly: the cardio Healthiness Study. Neurology 2005;65:1388–94.
Etminan M, Gill S, Samii A. The role of lipid-lowering drugs in cognitive function: a meta-analysis of observational studies. Pharmacotherapy 2003;23:726–30.
Dufouil C, Richard F, Fiévet N, et al. APOE genotype, Cholesterol levels level, lipid-lowering treatment, and dementia: the Three-City Study. Neurology 2005;64:1531–8.
Sparks DL, Kryscio RJ, Sabbagh MN, et al. reasonable risk of incident AD along with elective statin use in a clinical trial cohort. Curr Alzheimer Res 2008;5:416–21.
Hajjar I, Schumpert J, Hirth V, et al. The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol A Biol Sci Med Sci 2002;57:M414–8.
Sparks DL, Connor DJ, Sabbagh MN, et al. Circulating Cholesterol levels levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer’s disease: outcomes of the Alzheimer’s illness Cholesterol-Lowering Treatment (ADCLT) trial. Acta Neurol Scand Suppl 2006;185:3–7.
Li G, Higdon R, Kukull WA, et al. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology 2004;63:1624–8.
Arvanitakis Z, Schneider JA, Wilson RS, et al. Statins, incident Alzheimer disease, Adjustment in cognitive function, and neuropathology. Neurology 2008;70:1795–802.
Zandi PP, Sparks DL, Khachaturian AS, et al., Cache County Study Investigators. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry 2005;62:217–24.
Cutler N, Sramek J, Veroff A, et al. Effects of treatment along with simvastatin and pravastatin on cognitive function in patients along with hyper-cholesterolaemia. Br J Clin Pharmacol 1995;39:333–6.
Szwast SJ, Hendrie HC, Lane KA, et al. Association of statin use along with cognitive decline in elderly African Americans. Neurology 2007;69:1873–80.
Agostini JV, Tinetti ME, Han L, et al. Effects of statin use on muscle strength, cognition, and depressive symptoms in older adults. J Am Geriatr Soc 2007;55:420–5.
Feldman HH, Doody RS, Kivipelto M, et al., LEADe Investigators. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 2010;74:956–64.
McGuinness B, Craig D, Bullock R, et al. Statins for the treatment of dementia. Cochrane Database Syst Rev 2014;7:CD007514.
Trompet S, van Vliet P, de Craen AJ, et al. Pravastatin and cognitive function in the elderly. outcomes of the PROSPER study. J Neurol 2010;257:85–90.
Swiger KJ, Manalac RJ, Blumenthal RS, et al. Statins and cognition: a systematic review and meta-analysis of short- and long term cognitive effects. Mayo Clin Proc 2013;88:1213–21.
Ott BR, Daiello LA, Dahabreh IJ, et al. Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials. J Gen Intern Med 2015;30:348–58.
Rojas-Fernandez CH, Goldstein LB, Levey AI, et al. An assessment by the Statin Cognitive Safety Task Force: 2014 update. J Clin Lipidol 2014;8:S5–16.
Statin label changes. Med Lett Drugs Ther 2012;54:21.
Schretlen DJ, Munro CA, Anthony JC, et al. Examining the range of normal intraindividual variability in neuropsychological test performance. J Int Neuropsychol Soc 2003;9:864–70.
Doraiswamy PM, Steffens DC, McQuoid DR. Statin use and hippocampal volumes in elderly subjects at risk for Alzheimer’s disease: a pilot observational study. Am J Alzheimers Dis various other Demen 2004;19:275–8.
Sparks DL, Lemieux SK, Haut MW, et al. Hippocampal volume Adjustment in the Alzheimer illness Cholesterol-Lowering Treatment trial. Cleve Clin J Med 2008;75 Suppl 2:S87–93.
Dietschy JM, Turley SD. Thematic review series: brain lipids. Cholesterol levels metabolism in the central nervous system throughout early development and in the mature animal. J Lipid Res 2004;45:1375–97.
Locatelli S, Lütjohann D, Schmidt HH, et al. Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients along with hypercholesterolemia: evidence that simvastatin affects Cholesterol levels metabolism in the human brain. Arch Neurol 2002;59:213–6.
Simons M, Schwärzler F, Lütjohann D, et al. Treatment along with simvastatin in normocholesterolemic patients along with Alzheimer’s disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 2002;52:346–50.
Thelen KM, Lütjohann D, Vesalainen R, et al. Effect of pravastatin on plasma sterols and oxysterols in men. Eur J Clin Pharmacol 2006;62:9–14.
Thelen KM, Laaksonen R, Päivä H, et al. High-dose statin treatment does not change plasma marker for brain Cholesterol levels metabolism in patients along with moderately elevated plasma Cholesterol levels levels. J Clin Pharmacol 2006;46:812–6.
McFarland AJ, Anoopkumar-Dukie S, Arora DS, et al. Molecular mechanisms underlying the effects of statins in the central nervous system. Int J Mol Sci 2014;15:20607–37.
de Denus S, Spinler SA, Miller K, et al. Statins and liver toxicity: a meta-analysis. Pharmacotherapy 2004;24:584–91.
Calderon RM, Cubeddu LX, Goldberg RB, et al. Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma. Mayo Clin Proc 2010;85:349–56.
Bays H, Cohen DE, Chalasani N, et al. An assessment by the Statin Liver Safety Task Force: 2014 update. J Clin Lipidol 2014;8:S47–57.
Dormuth CR, Hemmelgarn BR, Paterson JM, et al. Use of higher potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases. BMJ 2013;346:f880.
Bangalore S, Fayyad R, Hovingh GK, et al., Treating to brand-new Targets Steering Committee and Investigators. Statin and the risk of renal-related severe side events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and various other placebo-controlled trials. Am J Cardiol 2014;113:2018–20.
de Zeeuw D, Anzalone DA, Cain VA, et al. Renal effects of atorvastatin and rosuvastatin in patients along with diabetes that have actually progressive renal illness (PLANET I): a randomised clinical trial. Lancet Diabetes Endocrinol 2015;3:181–90.
Savarese G, Musella F, Volpe M, et al. Effects of atorvastatin and rosuvastatin on renal function: a meta-analysis. Int J Cardiol 2013;167:2482–9.
Pullatt RC, Gadarla MR, Karas RH, et al. Tendon rupture associated along with simvastatin/ezetimibe therapy. Am J Cardiol 2007;100:152–3.
Contractor T, Beri A, Gardiner JC, et al. Is statin use associated along with tendon rupture? A population-based retrospective cohort analysis. Am J Ther 2015;22:377–81.
Khaw KT, Barrett-Connor E, Suarez L, et al. Predictors of stroke-associated mortality in the elderly. Stroke 1984;15:244–8.
Iso H, Jacobs DR Jr., Wentworth D, et al. Serum Cholesterol levels levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med 1989;320:904–10.
Yano K, Reed DM, MacLean CJ. Serum Cholesterol levels and hemorrhagic stroke in the Honolulu Heart Program. Stroke 1989;20:1460–5.
Wang X, Dong Y, Qi X, et al. Cholesterol levels levels and risk of hemorrhagic stroke: a systematic review and meta-analysis. Stroke 2013;44:1833–9.
Heart Protection Study Collaborative Group. Effects of cholesterol-lowering along with simvastatin on stroke and various other significant vascular events in 20536 individuals along with cerebrovascular illness or various other high-risk conditions. Lancet 2004;363:757–67.
Amarenco P, Bogousslavsky J, Callahan A III, et al. Stroke Prevention by Aggressive Reduction in Cholesterol levels Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549–59.
Hill C, Zeitz C, Kirkham B. Dermatomyositis along with lung involvement in a patient treated along with simvastatin. Aust N Z J Med 1995;25:745–6.
Fernández AB, Karas RH, Alsheikh-Ali AA, et al. Statins and interstitial lung disease: a systematic review of the literature and of Meals and Drug Administration side event reports. Chest 2008;134:824–30.
Shea BS, Sharma A, Mark EJ. Case records of the Massachusetts General Hospital. Case 14–2015. A 58-year-old woman along with shortness of breath. N Engl J Med 2015;372:1749–58.
Kim SY, Kim SJ, Yoon D, et al. A case of statin-induced interstitial pneumonitis because of rosuvastatin. Tuberc Respir Dis (Seoul) 2015;78:281–5.
Saad N, Camus P, Suissa S, et al. Statins and the risk of interstitial lung disease: a cohort study. Thorax 2013;68:361–4.
Ponnuswamy A, Manikandan R, Sabetpour A, et al. Association between ischaemic heart illness and interstitial lung disease: a case-regulate study. Respir Med 2009;103:503–7.
Xu JF, Washko GR, Nakahira K, et al., COPDGene Investigators. Statins and pulmonary fibrosis: the potential role of NLRP3 inflammasome activation. Am J Respir Crit Care Med 2012;185:547–56.
Lantuejoul S, Brambilla E, Brambilla C, et al. Statin-induced fibrotic nonspecific interstitial pneumonia. Eur Respir J 2002;19:577–80.
Coward WR, Marei A, Yang A, et al. Statin-induced proinflammatory response in mitogen-activated peripheral blood mononuclear cells through the activation of caspase-1 and IL-18 secretion in monocytes. J Immunol 2006;176:5284–92.
Schooling CM, Au Yeung SL, Freeman G, et al. The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials. BMC Med 2013;11:57.
Aijänseppä S, Kivinen P, Helkala EL, et al. Serum Cholesterol levels and depressive symptoms in elderly Finnish men. Int J Geriatr Psychiatry 2002;17:629–34.
Fang CY, Egleston BL, Gabriel KP, et al. Depressive symptoms and serum lipid levels in young adult women. J Behav Med 2013;36:143–52.
Sjögren B, Hamblin MW, Svenningsson P. Cholesterol levels depletion reduces serotonin binding and signaling via human 5-HT7(a) receptors. Eur J Pharmacol 2006;552:1–10.
You H, Lu W, Zhao S, et al. The partnership between statins and depression: a review of the literature. Expert Opin Pharmacother 2013;14:1467–76.
O’Neil A, Sanna L, Redlich C, et al. The impact of statins on psychological wellbeing: a systematic review and meta-analysis. BMC Med 2012;10:154.
Takada M, Fujimoto M, Yamazaki K, et al. Association of statin use along with sleep disturbances: data mining of a spontaneous reporting database and a prescription database. Drug Saf 2014;37:421–31.
Broncel M, Gorzelak-Pabís P, Sahebkar A, et al. Sleep Modifications adhering to statin therapy: a systematic review and meta-analysis of randomized placebo-controlled polysomnographic trials. Arch Med Sci 2015;11:915–26.
